Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 April 2025 | Story Tshepo Tsotetsi | Photo Supplied
Prof Tameshnie Deane
Prof Tameshnie Deane has been appointed an Acting Judge of the Free State High Court during the Faculty of Law’s milestone 80th anniversary.

Prof Tameshnie Deane, Vice-Dean: Research, Postgraduate Studies and Internationalisation in the Faculty of Law at the University of the Free State (UFS), has been appointed as an Acting Judge of the Free State High Court. Her appointment, which runs from 14 April to 30 May 2025, marks a significant moment for the faculty, and for the university’s broader academic and judicial community.

This is not Prof Deane’s first judicial appointment. Since 2019, she has served as an Acting Judge in various High Court divisions across South Africa, an experience that has shaped her legal thinking and affirmed her position as a respected voice in both academia and the courtroom.

“This appointment is an extraordinary milestone, both personally and professionally,” she said. “These appointments signify the recognition of my expertise and contributions to the legal field and academia over the years. Serving as an Acting Judge is a profound honour that reflects the trust placed in my ability to uphold justice, engage critically with complex legal matters, and contribute meaningfully to society.”

 

Bridging theory and the bench

Prof Deane is deeply committed to the idea that legal education and legal practice are not separate paths, but two sides of the same coin. Her work as a judge, she believes, enhances her ability to shape future legal minds, while her academic background brings fresh perspective to the courtroom.

“Serving as an Acting Judge offers invaluable insights into the practical application of legal principles, enriching my research and enabling me to mentor postgraduate students with a stronger emphasis on the real-world implications of their studies,” she said.

“Additionally, this experience deepens my understanding of comparative legal systems, which aligns perfectly with my focus on fostering internationalisation. On a broader professional level, it strengthens my ability to drive impactful scholarship and innovation, while advancing the university’s mission of academic excellence and global engagement.”

She added: “My dual grounding in academia and the legal profession equips me with a multidimensional perspective. From academia, I bring a deep commitment to critical thinking, analytical rigour, and intellectual curiosity, which can enhance the depth and breadth of judicial reasoning. From the legal field, I offer pragmatic insights and an unwavering dedication to justice.”

 

Institutional pride in a milestone year

The timing of the appointment is also significant. As the UFS Faculty of Law celebrates its 80th anniversary this year, Prof Deane’s appointment offers a moment to reflect on the faculty’s role in producing legal professionals who not only understand the law but actively shape its application.

“This moment highlights the enduring legacy of excellence, leadership, and innovation that the faculty has cultivated over 80 years,” she said. “It sends a powerful message to students and young academics: that dedication, perseverance, and a commitment to both intellectual and ethical standards can pave the way to significant achievements.”

Prof Serges Kamga, Dean of the Faculty of Law, echoed this sentiment, saying of Prof Deane’s appointment: “It illustrates our faculty’s commitment to producing legal professionals who actively influence and strengthen judicial practices. It bridges academic scholarship with judicial application, demonstrating our faculty’s dedication to shaping South Africa’s legal landscape and enhancing its national and international reputation.”

 

A message to young legal minds

Prof Deane believes the appointment sends a powerful message, especially to students and early-career academics. “Preparation for such a role requires a meticulous approach – both professionally and personally,” she said. “Professionally, it involves staying current with legal developments, understanding procedural rules, and immersing oneself in the dynamics of the court and the types of cases that may arise.”

“Personally, it demands resilience, adaptability, and a steadfast commitment to justice. However, sometimes opportunities like this are also shaped by a bit of luck – being in the right place at the right time, or meeting the right people who recognise your potential. Such moments serve as a reminder to remain open to possibilities and to always put one’s best foot forward, as you never know what doors may open.”

When asked about the types of cases she hopes to preside over, Prof Deane said her focus is on approaching every matter with diligence and fairness.

“As cases are assigned to us, my focus is not on selecting specific legal issues, but rather on approaching every matter with the utmost diligence and impartiality,” she said. “Each case, regardless of its nature, carries the potential to contribute to the development of law and have a significant impact on the lives of those involved. My aim is to engage deeply with every case, ensuring that decisions are both fair and informed, while appreciating the broader implications they may have for legal precedent and societal progress.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept